Indeed, compared to normal tissues, RNase T2 is significantly reduced in ovarian cancer, lymphoma, chronic lymphocytic leukemia, and melanoma (20), which may result in an increase in ARE- and GRE-genes and thereby promote tumor progression. Here, RNASET2 is linked to ovarian cancer.